Extended Data Table 1 Summary of confirmed objective response per RECIST v1.1 by BICR in the intention-to-treat population

From: Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

  1. Percentages may not total 100 because of rounding. aIncludes participants who experienced complete response or partial response. bCalculated based on the Miettinen and Nurminen method stratified by IMDC risk group (favorable versus intermediate versus poor) and geographic region (North America versus Western Europe versus rest of the world). cIncludes participants with postbaseline assessments available but not evaluable (that is, all postbaseline assessments with insufficient data for assessment of response per RECIST v1.1 or complete response, partial response or stable disease <6 weeks from randomization). dIncludes participants with no postbaseline assessment available for response evaluation.
Back to article page